Quince Therapeutics Inc - QNCX Total Company Value-to-Revenue Ratio

Quince Therapeutics (QNCX) - corporate logo

Global logistics risks and trade barriers are exerting external pressure on Quince Therapeutics. This chart on GURU.Markets illustrates how the company's EV/Sales multiple is reacting to these challenges, while the 0.00 metric confirms the current level. Business stability relies on innovative erythrocyte-based drug delivery, although the lack of operating cash flow leaves the company dependent on existing capital reserves.

QNCX Quince Therapeutics, Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 10/12/2026

Financial and market metric breakdowns for Quince Therapeutics (QNCX)

- share price and expert price forecast:
- cash and cash flow indicators:
Fundamental company valuation:QNCX (Quince)
Signature product of Quince

Geopolitical tensions and sanction barriers are hindering the clinical trials of Quince Therapeutics (QNCX), making the analysis of operational efficiency critical. The company's EV/Sales valuation compares the total enterprise value, including debt, with generated revenue, allowing investors to determine the extent of the premium paid for the asset. A decrease in this ratio indicates growing fundamental stability of the stock, limiting the risks of a further collapse in market capitalization.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)